Skin adverse events may predict lapatinib benefit in dogs with UC: full analysis

Dermatologic toxicity may carry prognostic value in dogs receiving lapatinib for urothelial carcinoma, according to a new retrospective study in Veterinary Dermatology. In a cohort of dogs treated for urothelial carcinoma, investigators found that alopecia, hyperpigmentation, and other skin-related adverse events were significantly more common with lapatinib plus piroxicam than with piroxicam alone, and that those events were linked with improved progression-free survival. (researchgate.net)

The finding builds on a growing body of work around lapatinib in canine urothelial carcinoma. In a 2022 Scientific Reports trial, dogs treated with lapatinib plus piroxicam had better tumor responses and longer survival than matched dogs treated with piroxicam alone, with the greatest benefit seen in tumors with higher HER2 expression. That study also suggested the regimen was broadly tolerable, with most adverse events falling in the mild-to-moderate range. (pubmed.ncbi.nlm.nih.gov)

In the new retrospective analysis, researchers evaluated 85 dogs that received lapatinib with piroxicam and compared them with 42 dogs given piroxicam alone. According to the study abstract, the lapatinib-treated group had a 4.4-fold increased risk of dermatological adverse events. The reported events included alopecia and hyperpigmentation, and the authors concluded that these changes may serve as biomarkers of improved treatment efficacy. (researchgate.net)

That interpretation is biologically plausible, based on both veterinary and human oncology experience. Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor, and skin toxicities are a recognized class effect of EGFR-pathway inhibition. A human meta-analysis found lapatinib significantly increased the risk of rash, pruritus, stomatitis, and hand-foot skin reaction, while practical management guidance in human oncology has long treated rash as a common and clinically meaningful toxicity requiring monitoring rather than automatic discontinuation. (pubmed.ncbi.nlm.nih.gov)

Direct outside commentary on this specific canine paper was limited in the sources available, but the broader veterinary literature points in the same direction: targeted therapies in dogs can produce distinctive cutaneous adverse effects, and those effects may become more important as precision oncology expands in practice. Reviews of kinase inhibitors in veterinary oncology have highlighted lapatinib as an emerging option in canine solid tumors, including urothelial carcinoma, while noting that skin reactions and hepatobiliary effects remain part of the monitoring picture. (mdpi.com)

Why it matters: For veterinary professionals, the study may change the framing of skin toxicity from a straightforward complication to a potentially informative clinical signal. That doesn't mean every lesion should be tolerated without intervention, but it does suggest dermatologic monitoring should be deliberate, consistent, and tied to treatment decision-making. If future work confirms these events as pharmacodynamic markers, clinicians may be better positioned to reassure pet parents when mild coat or pigment changes appear, and to distinguish manageable on-target effects from toxicities that truly warrant dose interruption or discontinuation. (researchgate.net)

The paper also matters because canine urothelial carcinoma remains a difficult disease to manage, and targeted options are still limited. Piroxicam has been a longstanding backbone of treatment, but multiple studies over the years have shown the need for more effective approaches, whether through cytotoxic combinations, BRAF-targeted therapy, or HER2-directed treatment such as lapatinib. Any marker that helps clinicians predict benefit, maintain adherence, or tailor supportive care could improve real-world use of these newer regimens. (pmc.ncbi.nlm.nih.gov)

What to watch: The next step is prospective validation, ideally with standardized grading of dermatologic events, clearer timing of onset, and analysis of whether specific skin findings correlate with HER2 status, dose intensity, or overall survival. If those data emerge, dermatologic adverse events could move from being an anecdotal observation to a practical monitoring tool in canine oncology. (researchgate.net)